Table 1.

Treatment-related AEs occurring in at least 5% of patients or with any event of grade 3 or higher^a in the eganelisib monotherapy cohort

n (%)	Eganelisib dose escalation (Part A)						Eganelisib dose expansion (Part D: 60 mg) (n=20)
	10–30 mg (n=12)		40 mg (n=4)		60 mg (n=3)
	Any grade	G≥3	Any grade	G≥3	Any grade	G≥3b	Any grade	G≥3
Any treatment-related TEAE	6 (50)	-	3 (75)	-	2 (67)	2 (67)	14 (70)	8 (40)
AST increased	1 (8)	-	2 (50)	-	1 (33)	1 (33)	9 (45)	6 (30)
ALT increased			2 (50)	-	1 (33)	1 (33)	8 (40)	6 (30)
Rashc	1 (8)	-	2 (50)	-			8 (40)	2 (10)
Fatigue	1 (8)	-	1 (25)	-			3 (15)	-
Headache	2 (17)	-					1 (5)	-
Blood ALP increased					1 (33)	-	2 (10)	2 (10)
Dyspnea							2 (10)	1 (5)
Amylase increased	1 (8)	-					1 (5)	-
Lipase increased	1 (8)	-					1 (5)	-
WBC decreased			1 (25)	-			1 (5)	-
Blood bilirubin increased							1 (5)	1 (5)
Hypercalcemia					1 (33)	1 (33)

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; DLT, dose-limiting toxicity; G≥3, grade 3 or higher; TEAE, treatment-emergent adverse event; WBC, white blood cell count.

^aAll events were grade 3 except for grade 4 increases in ALT and bilirubin that both occurred in the same patient.

^bNo grade ≥3 events occurred during the DLT observation period (first treatment cycle).

^cIncludes preferred terms pruritis, rash, and rash maculopapular.